Promising Advances in Bladder Cancer Treatment and Personalized Care

Recent developments in bladder cancer treatments, as highlighted in an editorial by Dr. Matthew Milowsky, are offering renewed hope for patients, particularly those with high-risk muscle-invasive disease. **Platinum-based chemotherapy**, the traditional treatment, is now being enhanced by **immune checkpoint inhibitors**. These inhibitors work by **unlocking the immune system**, allowing it to better attack cancer cells. The **NIAGARA trial** successfully combined such inhibitors with chemotherapy, showing a marked increase in two-year survival rates and a reduction in cancer recurrence for patients who received this combination therapy before and after surgery. **Enfortumab vedotin**, an antibody-drug conjugate approved by the FDA, is part of these groundbreaking treatments. The trial's outcome represents the first significant shift in the approach to muscle-invasive bladder cancer in a randomized phase 3 setting. However, the trial also revealed limitations, particularly in its design, which did not allow for determining the individual effectiveness of treatment components given before and after surgery. **Future trials will need to address these limitations** to ensure the best outcomes without undue side effects. The use of **predictive biomarkers** is seen as the next frontier. These biomarkers can help in identifying patients at a higher risk of recurrence, thus enabling more personalized treatments. **Circulating tumor DNA** is one such promising tool, helping pinpoint patients who would benefit most from perioperative therapies, ultimately aiming to reduce unnecessary treatments and their side effects.